Phase

Article contentEDMONTON, Alberta, Feb. 15, 2024 (GLOBE NEWSWIRE) — Regenx Tech Corp., (the “Company” or “Regenx”) (CSE: RGX) (OTCQB: RGXTF) (FSE: YRS WKN:A2DSW3) announces the first shipment of its black powder concentrate to a refiner from…

© Reuters. LOS ANGELES - Puma Biotechnology, Inc. (NASDAQ: NASDAQ:) has commenced a Phase II clinical trial to evaluate the efficacy of its drug alisertib in treating extensive stage small cell lung cancer (SCLC), the company…

cagkansayin Australian biotech CSL Limited (OTCQX:CSLLY) fell ~4% on Monday, marking its biggest intraday loss in more than four months after its Phase 3 AEGIS-II trial, one of its key clinical programs, failed. The global trial was…

© Reuters. SAN JOSE, Calif. – Anixa Biosciences, Inc. (NASDAQ: NASDAQ:), a biotech company specializing in cancer treatment, has started treating the fourth patient in its phase 1 clinical trial for a novel ovarian cancer therapy.…

Ionis Pharmaceuticals (NASDAQ:IONS) on Monday announced positive topline Phase 3 trial results for its donidalorsen drug candidate for hereditary angioedema (HAE). The Phase 3 OASIS-HAE study found donidalorsen met the primary endpoint of…

This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire…

juststock NKGen Biotech (NASDAQ:NKGN) said it has dosed its first patient in a Phase 1/2a study of its cell therapy SNK01 in the treatment of moderate Alzheimer’s disease, AD. The biotech company said the Phase 1 portion of the study…

SAND, the native token of metaverse platform ‘The Sandbox,’ has gained over 40% in the past month, driven by a broader market resurgence that pushed its price to $0.61, a level last seen in April this year. SAND is one of…

Breadcrumb Trail LinksPMN BusinessSign up for the Green Daily newsletter for comprehensive coverage of the climate summit right in your inbox.Author of the article:Bloomberg NewsJennifer A. Dlouhy and John AingerPublished Dec 03, 2023  •  4…

Professor25/iStock via Getty Images DBV Technologies (NASDAQ:DBVT) reported positive two-year data from an ongoing Phase 3 study extension for its peanut allergy treatment Viaskin Peanut in toddlers aged one to three years old. The…